Hoosier Cancer Research Network

• NCT03451331

  Collaborator, Phase 2, Completed, 49 people, 1 Mar 2018

• NCT02549209

  Collaborator, Phase 2, Completed, 46 people, 15 Sept 2015

• NCT02382406

  Collaborator, Phase 1/2, Terminated, 46 people, 6 Mar 2015

• NCT02365766

  Collaborator, Phase 1/2, Completed, 83 people, 19 Feb 2015

• NCT01736917

  Collaborator, Phase 2, Completed, 65 people, 29 Nov 2012

• NCT01681433

  Collaborator, Phase 2, Terminated, 72 people, 10 Sept 2012

• NCT01624493

  Phase 1/2, Withdrawn, 0 people, 20 Jun 2012

• NCT01524991

  Phase 2, Completed, 36 people, 2 Feb 2012

• NCT01215136

  Collaborator, Phase 2, Terminated, 36 people, 6 Oct 2010

• NCT01177683

  Collaborator, Phase 1/2, Terminated, 32 people, 9 Aug 2010

• NCT01074970

  Phase 2, Completed, 135 people, 24 Feb 2010

• NCT01034631

  Phase 1/2, Completed, 154 people, 17 Dec 2009

• NCT00859339

  Collaborator, Phase 2, Terminated, 9 people, 11 Mar 2009

• NCT00773474

  Collaborator, Phase 2, Terminated, 29 people, 16 Oct 2008

• NCT00632541

  Phase 2, Terminated, 18 people, 10 Mar 2008

• NCT00613626

  Phase 2, Completed, 74 people, 13 Feb 2008

• NCT00526799

  Collaborator, Phase 1/2, Terminated, 30 people, 10 Sept 2007

• NCT00234494

  Collaborator, Phase 2, Completed, 45 people, 7 Oct 2005

• NCT00216073

  Phase 2, Terminated, 11 people, 22 Sept 2005

• NCT00216021

  Phase 2, Completed, 25 people, 22 Sept 2005

• Association of sodium-glucose co-transport protein 2 inhibitor use with clinical outcomes in patients receiving immune checkpoint inhibitors: a pan-tumor propensity-matched analysis

  Grants or research support, 6 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov